AstraZeneca will pay CSPC upfront fee of $110 million Additional potential payments of up to $5.22 billion to CSPC Deal latest of AstraZeneca efforts to bolster China business, AI The deal marks ...

AstraZeneca has returned to recent licensing partner CSPC Pharmaceutical with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases. The Friday ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.

AstraZeneca has forged a wide-ranging collaboration with Chinese biotech CSPC Pharma that will focus on the use of artificial intelligence (AI) to find new medicines across a range of diseases.

AstraZeneca announced earlier this year plans to invest $2.5 billion in China. British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC ...

(Reuters) -AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for ...